CoChat

Fractional synthesis and clearance rates for amyloid β

Open access
Edland, Steven D, Galasko, Douglas R · 2011 · Nature Medicine
Cited by 7

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

To the Editor: We are writing regarding the 2006 publication of a new stable isotope labeling kinetics (SILK) protocol for assessing the fractional synthesis and clearance rates of amyloid b (Ab) in the brain1. This protocol has been used to demonstrate the relatively accelerated rate of turnover of Ab peptides in the brain1 and to assess the effect of drugs on Ab production2. However, we are concerned that aspects of the protocol have not been fully appreciated, raising questions about the interpretation of findings from the protocol. Our main concern is the estimation of fractional clearance rates for Ab. In the Alzheimer’s disease literature, clearance usually refers to degradation or removal of Ab by proteolytic enzymes, microglia and blood-brain barrier transport. Several studies have assumed that clearance rates measured by the SILK protocol reflect these factors1–3, but we suggest this is not the case. Understanding the distinction between clearance of Ab and the phenomenon measured by the SILK protocol requires knowledge of details of the protocol. In brief, the protocol1 consists of a production phase, during which C6-labeled leucine (C6-leucine) is infused intravenously and the proportion of synthesized and secreted Ab labeled with C6-leucine at amino acid 17 is measured, and a clearance phase, during which the proportion of Ab labeled with C6-leucine is monitored for some hours after cessation of the peripheral infusion. Cerebrospinal fluid (CSF) is sampled with a catheter inserted between the third and fourth lumbar vertebrae, with hourly sampling for 36 h. During peripheral C6-leucine infusion, approximately 10% of leucine available for protein synthesis is C6 labeled. The rate at which the proportion of Ab labeled with C6-leucine approaches the saturation proportion of 10% provides an estimate of the synthesis rate of Ab1. Interpretation of changes in this proportion after the production phase is less clear. The key observation in regard to our above concern is that the protocol does not measure the absolute amount of newly synthesized Ab but rather the relative proportion of Ab labeled with C6-leucine at amino acid 17 (ref. 1). Because the processes of degradation or removal of Ab by proteolytic enzymes, microglia and blood-brain barrier transport do not distinguish between labeled and unlabeled Ab, they do not influence the relative proportion of these molecules in fluids leaving the parenchyma (Fig. 1). The SILK protocol measures proportions, and therefore findings by the SILK protocol do not reflect the influence of parenchymal clearance on Ab levels. What does the clearance rate obtained by the SILK protocol measure? We have implemented computer models to characterize this aspect of the protocol (Supplementary Methods). As originally described1, clearance rates are estimated using data from hours 24 through 36 of the protocol. By hour 24 of the protocol, neuronal APP amyloid precursor protein and secreted Ab will have turned over one or more times since the end of the infusion, and the proportion of newly secreted Ab originating within the brain that is labeled will approach zero. Nonetheless, a measurable fraction of labeled Ab remains within the substantial volume of CSF contained in the subarachnoid space at this time. This fraction declines logarithmically (as described in the original protocol1). Logarithmic decline is consistent with expectation for a process of dilution by bulk flow and turnover of CSF. For example, a person with a CSF volume of 150 ml and production of CSF of 20 ml h–1 at the choroid plexus and other brain sites will clear CSF labeled Ab at a rate of 20/150 (13.33%) per hour (Supplementary Fig. 1). That is, rates measured at the clearance phase of the SILK protocol reflect CSF turnover. We conclude that there is little reason to extend CSF sampling beyond the production phase of the protocol and that time and resources could be saved, and study subject burden avoided, by ending the protocol at hour 15. Our second concern is that fractional synthesis rate estimates by the protocol are underestimates of the actual synthesis rates. This is because the mixture of labeled and unlabeled Ab molecules in fluids leaving the brain is diluted by a large volume of CSF containing only unlabeled Ab before being sampled at the lumbar spine (Fig. 1). Dilution slows the rate at which the proportion of Ab that is labeled approaches 10% saturation. We have demonstrated by computer simulation that this downward bias may be substantial (Supplementary Results). Moreover, the downward bias is a function of CSF volume, such that persons with larger CSF volume have a larger downward bias (Supplementary Fig. 1). This is relevant to the recent observation that synthesis rate estimates by the SILK protocol are comparable in individuals with sporadic Alzheimer’s disease and age-match controls3. On the basis of the greater volume of circulating CSF in people with Alzheimer’s disease, one would expect slower observed rates in affected individuals and faster observed rates in controls if synthesis rates were comparable in these two groups (Supplementary Fig. 2). The lack of an observed difference3 may simply reflect small sample size and type II error. Alternatively, if this finding holds in larger samples, it would be consistent with higher neuronal Ab synthesis rates in sporadic Alzheimer’s disease. Figure 1 During the infusion of C6-labeled leucine, the fraction of labeled Ab secreted by neurons increases from 0% to a theoretical maximum of 10% at the neuronal fractional synthesis rate. Within the brain, secreted molecules are cleared by processes that do not discriminate labeled from unlabeled molecules and do not influence the fraction that is labeled. Labeled molecules leaving the brain are diluted by a large volume of CSF containing unlabeled Ab before being sampled from the lumbar subarachnoid space.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2495

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Edland, S. D., & Galasko, D. R.
Venue
Nature Medicine
Published
2011-10
Volume
17
Issue
10
Pages
1178-1179
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W2067052768
Cited by
7
References
2
FWCI
0.96
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.